The genome-wide survival association study was performed on 14,406 AD case samples and 25,849 control samples from the International Genomics of Alzheimer’s Project (IGAP) consortium (see Table 1a, Huang et al., 2017 for details). The final IGAP meta-analysis dataset consists of samples from the Alzheimer’s Disease Genetics Consortium (ADGC), Genetic and Environmental Risk in Alzheimer’s Disease (GERAD), European Alzheimer’s Disease Initiative (EADI), and Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE). The study cohorts consist of case–control and longitudinal cohorts and are described in detail in online methods of (Huang et al., 2017). 8,253,925 imputed and genotyped SNPs passed quality control and were included for meta-analysis across all cohorts. There was no evidence of genomic inflation (λ = 1.026).
Four loci showed genome-wide significant associations with AAOS: BIN1 (P = 3.9x10−10), MS4A (P = 2.3x10−9), PICALM (P = 9.1x10−12) and APOE (P = 7.8x10−52)). Four other AD risk loci previously reported in the IGAP GWAS showed associations that reached suggestive significance: CR1 (P = 1.2x10−6), SPI1 (previously labeled as CELF1 in the 2013 IGAP GWAS paper1; P = 8.4x10−6), SORL1 (P = 5.5x10−6) and FERMT2 (P = 2.3x10−6). We also identified 14 loci that reached suggestive significance in the survival analysis, three of which (rs116341973, rs1625716 and rs11074412) were nominally associated with AD risk.
The p-value data is generally available to all users using the link below; however, gaining access to the complete dataset requires a formal data request.
